A 64-year-old man with long-standing type 2 diabetes and obesity is reviewed in clinic. His HbA1c remains 76 mmol/mol despite maximal tolerated Metformin. According to current NICE guidance, which class of drug is now recommended as first-line add-on with evidence of cardiovascular benefit?